Healthcare
TAO Synergies Inc.(TAOX)
Live Price
Offline$3.85
+1.05% today
1Y Change
-11.40%
Window
Jun 20, 2025 → Jun 5, 2026
- Market Cap
- $20.00M
- Revenue Growth
- 0.0%
- EPS Growth
- 0.0%
- Dividend Yield
- 0.0%
Coverage: 241 bars · Jun 20, 2025 → Jun 5, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
TAO Synergies Inc. (TAOX) is a Healthcare stock with a market cap of $20.00M and listed on NASDAQ. The stock last traded around $3.85 and down 11.4% across the available one-year price window (Jun 20, 2025 → Jun 5, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of 0.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS 0.0%, free cash flow -30.9% with operating margin -3259.2% and ROIC -40.6%. Valuation already assumes a fairly strong business story at price/sales 58.6. Stock Foundry combines TAOX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
-3259.2% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Jun 3, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is 0.0%, while operating margin sits near -3259.2%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 7, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -8.8% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Δ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Jun 3, 2026 | — | +2.3% | — | — |
2026 May 13, 2026 | +96.4% | +1.4% | -19.3% | — |
2026 Feb 25, 2026 | — | -8.6% | +1.8% | +37.7% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TAOX
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TAOX Max Drawdown
-67.73%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TAOX and SPY.
Company Overview
TAO Synergies Inc.
NASDAQ Global Market
Clinical-stage biopharmaceutical company developing a bryostatin‑1 platform for Alzheimer’s and other neurodegenerative/cognitive diseases. Also pivoting to a digital-asset treasury strategy focused on acquiring and staking TAO cryptocurrency.
- Leadership
- Joshua N. Silverman
- IPO Date
- Jul 2, 2025
- Employees
- 4
- Street Address
- 1185 Avenue of the Americas, 3rd Floor
- Mailing
- New York, 10036
- Region
- New York, US
- Reporting Currency
- USD
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- —
- EV/EBITDA
- —
- Price/Sales
- 58.6
- Price/Book
- 0.4
Growth
- Revenue
- 0.0%
- EPS
- 0.0%
- Free Cash Flow
- -30.9%
Profitability
- Gross Margin
- 100.0%
- Operating Margin
- -3259.2%
- Net Margin
- -9609.2%
- ROE
- -182.5%
- ROIC
- -40.6%
Balance Sheet
- Debt/Equity
- —
- Current Ratio
- 13.99
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.